Sander Binderow, MD
Colon & Rectal Surgery · Atlanta, GANPI 1023086238
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by TELA Bio, Inc. at 28.2% of the total. Reporting peaked in 2022 at $5,351 and has fallen 93.1% since, to $368 in 2025.
Across 175 payments — averaging $112.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TELA Bio, Inc.$6K
- Intuitive Surgical$4K
- AbbVie$4K
- Acell, Inc.$1K
- Axonics, Inc.$997
- Medtronic$925
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$2751%
- Travel & lodging$11,23657%
- Food & beverage$5,87630%
- Education$2,25011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TELA Bio, Inc. | 24 | $5,533 |
| Intuitive Surgical | 21 | $4,380 |
| AbbVie(2 entities) | 23 | $3,685 |
| Acell, Inc. | 11 | $1,117 |
| Axonics, Inc. | 17 | $997 |
| Medtronic(2 entities) | 13 | $925 |
| Asensus Surgical, Inc. | 5 | $843 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $559 |
| Aroa Biosurgery Incorporated | 5 | $470 |
| Baxter Healthcare | 6 | $242 |
| Davol Inc. | 8 | $240 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $142 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $84 |
| Innovation Technologies Inc | 1 | $70 |
| Braintree Laboratories, Inc. | 3 | $57 |
| La Jolla Pharmaceutical Company | 2 | $46 |
| Johnson & Johnson | 1 | $33 |
| Vertex | 1 | $28 |
| Vioptix Inc | 1 | $26 |
| Merck | 2 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Mimedx Group, Inc. | 1 | $19 |
| Palette Life Sciences, Inc. | 1 | $18 |
| Integra Lifesciences Corporation | 1 | $17 |
| Convatec Inc. | 1 | $16 |
| Solventum Corporation | 1 | $14 |
| Prescient Surgical | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex)$4,280
- Da Vinci Surgical System$3,924
- NATRELLE SALINE-FILLED BREAST IMPLANTS$2,817
- REVOLVE$1,409
- ALLODERM$1,274
- OviTex 2S$871
- Senhance Surgical Robotics System$740
- Axonics r-SNM System$587
- INTERSTIM$573
- Bulkamid$475
- GATTEX$275
- STRATTICE$136
- No Related Product$121
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS$107
How this compares
$19,637 in reported general payments places this provider in the 80th percentile of 66 colon & rectal surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 145 | $9,973 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 11 | $1,867 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 53 | $562 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 17 | $353 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 18 | $258 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 31 | $240 |
| Neomycin Sulfate | 35 | $191 |
| Metronidazole | 36 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ferring Pharmaceuticals Inc.Clenpiq | $19 | $1,86711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 66 colon & rectal surgery providers in Georgia.
Other colon & rectal surgery in Atlanta
- Patrick SullivanAtlanta$41K
- Daniel Sarmiento GarzonAtlanta$14K
- Joseph MarenoAtlanta$13K
- Jessica LamAtlanta$8K
- Evan FeldmanAtlanta$7K
- Cici ZhangAtlanta$5K
- Ellen CaparosaAtlanta$5K
- Monica HumAtlanta$5K
- Gie YuAtlanta$3K
- Stephanie PappasAtlanta$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.